Poll results: Improved PFS suffices for FDA approvals

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

Progression-free survival (PFS) is a perfectly reasonable basis for the US Food and Drug Administration (FDA) to approve new drug indications, according to ONI readers.

Progression-free survival (PFS) is a perfectly reasonable basis for the US Food and Drug Administration (FDA) to approve new drug indications, according to ONI readers. Of those who responded to ONI’s July poll question-“Should FDA accept progression-free survival as a basis for approval of new drug indications?”--half (50%) answered in the affirmative.

 

The poll was linked to the article, “Bevacizumab improves PFS in advanced breast cancer.” Bevacizumab (Avastin) received FDA approval as first-line therapy with paclitaxel for HER2-negative metastatic breast cancer based on improved PFS in the E2100 trial (July 2008, page 28).

 

PFS is second only to response rate as the most frequently employed endpoint for oncologic drug approval, according to Richard Pazdur, MD, director of FDA’s Office of Oncology Drug Products “Cancer drugs pipeline is healthy, says head of oncologic drug approval for FDA,” (August 2008, page 24).

 

To respond to this month’s poll question on reimbursement (page 2), visit cancernetwork.com.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content